v3.26.1
Segment Information - Schedule of Reconciliation of Collaboration Revenue and Segment Expenses to Net Loss for Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Collaboration revenue $ 3,165   $ 5,200   $ 5,758 $ 11,673
General and administrative 7,516   10,495   15,777 20,135
Interest income 1,528   2,831   3,440 6,122
Other income 411   427   846 845
Income tax provision 20   15   34 52
Net loss (24,473) $ (27,937) (33,382) $ (31,021) (52,410) (64,403)
Single reportable segment            
Segment Reporting [Line Items]            
Collaboration revenue 3,165   5,200   5,758 11,673
Internal research and development [1] 7,781   10,263   15,874 20,221
Facilities and other research and development [2] 5,204   7,852   11,329 15,939
General and administrative [2] 7,516   10,495   15,777 20,135
Interest income 1,528   2,831   3,440 6,122
Other income 411   427   846 845
Income tax provision 20   15   34 52
Net loss (24,473)   (33,382)   (52,410) (64,403)
Single reportable segment | Anti-tau antibody program (VY7523)            
Segment Reporting [Line Items]            
External research and development [3] 1,959   3,705   4,336 7,954
Single reportable segment | Tau silencing gene therapy program (VY1706)            
Segment Reporting [Line Items]            
External research and development [3] 2,873   3,414   8,509 6,588
Single reportable segment | SOD1 silencing gene therapy program            
Segment Reporting [Line Items]            
External research and development [3] 0   380   0 2,266
Single reportable segment | Partnered programs            
Segment Reporting [Line Items]            
External research and development [3],[4] 1,787   1,898   2,459 2,889
Single reportable segment | Other programs and platforms            
Segment Reporting [Line Items]            
External research and development [3],[5] $ 2,437   $ 3,818   $ 4,136 $ 6,999
[1] Internal research and development consist of employee-related expenses, including salaries, benefits, and stock-based compensation expense.
[2] Depreciation and amortization expense is allocated between general and administrative and facilities and other research and development.
[3] External research and development is allocated to the Company’s programs and platforms and includes laboratory supplies and non-employee consultant and contractor costs.
[4] Partnered programs include programs in which the Company is collaborating with partners to develop AAV gene therapy products and product candidates under the Company’s 2019 and 2023 Neurocrine Collaboration Agreements and the License and Collaboration Agreement the Company entered into with Novartis on December 28, 2023.
[5] Other programs and platforms consist of expenses related to other early research programs and platforms that are not considered quantitatively and qualitatively significant, including capsid discovery, non-viral delivery, and early research programs.